Strategy

Our objective is to be a leading developer of innovative products that provide safer and more effective diagnosis and treatment of AF. Our primary goal is to commercialize all of our REVELATION(R) series of ablation products for the treatment of AF in the electrophysiology market.

Our Surgical Ablation System (SAS), a micro-catheter-based surgical probe coupled to the INTELLITEMP(R), a RF energy management device, received 510(k) clearance for use in the United States in January 2003. Due to our focus on the EP market, we do not currently plan to market our SAS ourselves, and are currently seeking to sell or otherwise...